Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial

BACKGROUND: High-dose donepezil is currently prescribed for patients with Alzheimer’s disease (AD) who showed poor or waning response to a lower dose at the risk of increasing cholinergic side effects. However, the adverse events (AEs) depending on the method of dose escalation have not been clarifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Yun Jeong, Han, Hyun Jeong, Youn, Young Chul, Park, Kyung Won, Yang, Dong Won, Kim, SangYun, Kim, Hwa Jung, Kim, Ji Eun, Lee, Jae-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492390/
https://www.ncbi.nlm.nih.gov/pubmed/31039806
http://dx.doi.org/10.1186/s13195-019-0492-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492390/
https://www.ncbi.nlm.nih.gov/pubmed/31039806
http://dx.doi.org/10.1186/s13195-019-0492-1

Ejemplares similares